Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495906 | 0.88 | CREBBP (0.55) | SMN1; SMN2KDM4EMEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL1495905 | 0.87 | CREBBP (0.54) | SMN1; SMN2KDM4EMEN1KMT2AGAA | |
| SCHEMBL6174157 | 0.86 | MCHR1 (0.62) | SMN1; SMN2KDM4EMEN1KMT2AGAA | |
| SCHEMBL1495995 | 0.86 | KDM4E (0.50) | SMN1; SMN2KDM4EMEN1KMT2AGAA | |
| SCHEMBL1495991 | 0.82 | KDM4E (0.46) | SMN1; SMN2KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL7445354 | 0.81 | ALDH1A1 (0.59) | SMN1; SMN2KDM4EMEN1KMT2AGAA | |
| SCHEMBL5681637 | 0.80 | KDM4E (0.92) | KDM4EKMT2AALDH1A1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL7447159 | 0.80 | ALDH1A1 (0.58) | SMN1; SMN2KDM4EMEN1KMT2AGAA | |
| SCHEMBL20504536 | 0.80 | ACHE (0.56) | SMN1; SMN2KDM4EMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL8693860 | 0.79 | KDM4E (0.90) | SMN1; SMN2KDM4EKMT2AALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | SMN1; SMN2 4623/4885KDM4E 2842/4885MEN1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.